Impact of reducing day 1 dexamethasone dose in anthracycline-containing regimens on acute gastrointestinal symptoms associated with breast cancer treatment

Abstract The potential of steroid sparing from day 2 onward is reported in anthracycline-containing regimens for breast cancer treatment. We evaluated whether the reduction of dexamethasone (DEX) dose from 9.9 to 6.6 mg on day 1 is possible in anthracycline-containing treatments. Patients receiving...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yoshitaka Saito, Yoh Takekuma, Takashi Takeshita, Mitsuru Sugawara
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/d243387fb18d4255bb27707e93a9f380
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d243387fb18d4255bb27707e93a9f380
record_format	dspace
spelling	oai:doaj.org-article:d243387fb18d4255bb27707e93a9f3802021-12-05T12:12:55ZImpact of reducing day 1 dexamethasone dose in anthracycline-containing regimens on acute gastrointestinal symptoms associated with breast cancer treatment10.1038/s41598-021-02765-32045-2322https://doaj.org/article/d243387fb18d4255bb27707e93a9f3802021-12-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-02765-3https://doaj.org/toc/2045-2322Abstract The potential of steroid sparing from day 2 onward is reported in anthracycline-containing regimens for breast cancer treatment. We evaluated whether the reduction of dexamethasone (DEX) dose from 9.9 to 6.6 mg on day 1 is possible in anthracycline-containing treatments. Patients receiving anthracycline-containing regimens were divided into control (9.9 mg DEX on day 1) and reduced (6.6 mg DEX on day 1) groups, and retrospectively evaluated. The complete response (CR) rate and the incidence and severity of nausea, vomiting, anorexia, and fatigue were evaluated. The CR rate in the acute phase (day 1) was 63.1% and 38.1% in the control and reduced groups, respectively, with significant difference (P = 0.01) between the groups. However, no difference was found in the delayed phase (days 2–7). The incidence of anorexia and vomiting during treatment was not statistically different. Severity of nausea tended to, but not statistically, worsen while anorexia significantly worsened in the reduced group. Multivariate analysis suggested that patients < 55 years, with non- or less-alcohol drinking habit (< 5 days/week), and administered reduced-DEX dosage on day 1, have a higher risk of acute nausea development. Thus, reducing day 1 DEX dose in anthracycline-containing regimens is not suitable for acute nausea management.Yoshitaka SaitoYoh TakekumaTakashi TakeshitaMitsuru SugawaraNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Yoshitaka Saito Yoh Takekuma Takashi Takeshita Mitsuru Sugawara Impact of reducing day 1 dexamethasone dose in anthracycline-containing regimens on acute gastrointestinal symptoms associated with breast cancer treatment
description	Abstract The potential of steroid sparing from day 2 onward is reported in anthracycline-containing regimens for breast cancer treatment. We evaluated whether the reduction of dexamethasone (DEX) dose from 9.9 to 6.6 mg on day 1 is possible in anthracycline-containing treatments. Patients receiving anthracycline-containing regimens were divided into control (9.9 mg DEX on day 1) and reduced (6.6 mg DEX on day 1) groups, and retrospectively evaluated. The complete response (CR) rate and the incidence and severity of nausea, vomiting, anorexia, and fatigue were evaluated. The CR rate in the acute phase (day 1) was 63.1% and 38.1% in the control and reduced groups, respectively, with significant difference (P = 0.01) between the groups. However, no difference was found in the delayed phase (days 2–7). The incidence of anorexia and vomiting during treatment was not statistically different. Severity of nausea tended to, but not statistically, worsen while anorexia significantly worsened in the reduced group. Multivariate analysis suggested that patients < 55 years, with non- or less-alcohol drinking habit (< 5 days/week), and administered reduced-DEX dosage on day 1, have a higher risk of acute nausea development. Thus, reducing day 1 DEX dose in anthracycline-containing regimens is not suitable for acute nausea management.
format	article
author	Yoshitaka Saito Yoh Takekuma Takashi Takeshita Mitsuru Sugawara
author_facet	Yoshitaka Saito Yoh Takekuma Takashi Takeshita Mitsuru Sugawara
author_sort	Yoshitaka Saito
title	Impact of reducing day 1 dexamethasone dose in anthracycline-containing regimens on acute gastrointestinal symptoms associated with breast cancer treatment
title_short	Impact of reducing day 1 dexamethasone dose in anthracycline-containing regimens on acute gastrointestinal symptoms associated with breast cancer treatment
title_full	Impact of reducing day 1 dexamethasone dose in anthracycline-containing regimens on acute gastrointestinal symptoms associated with breast cancer treatment
title_fullStr	Impact of reducing day 1 dexamethasone dose in anthracycline-containing regimens on acute gastrointestinal symptoms associated with breast cancer treatment
title_full_unstemmed	Impact of reducing day 1 dexamethasone dose in anthracycline-containing regimens on acute gastrointestinal symptoms associated with breast cancer treatment
title_sort	impact of reducing day 1 dexamethasone dose in anthracycline-containing regimens on acute gastrointestinal symptoms associated with breast cancer treatment
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/d243387fb18d4255bb27707e93a9f380
work_keys_str_mv	AT yoshitakasaito impactofreducingday1dexamethasonedoseinanthracyclinecontainingregimensonacutegastrointestinalsymptomsassociatedwithbreastcancertreatment AT yohtakekuma impactofreducingday1dexamethasonedoseinanthracyclinecontainingregimensonacutegastrointestinalsymptomsassociatedwithbreastcancertreatment AT takashitakeshita impactofreducingday1dexamethasonedoseinanthracyclinecontainingregimensonacutegastrointestinalsymptomsassociatedwithbreastcancertreatment AT mitsurusugawara impactofreducingday1dexamethasonedoseinanthracyclinecontainingregimensonacutegastrointestinalsymptomsassociatedwithbreastcancertreatment
_version_	1718372162289532928

Impact of reducing day 1 dexamethasone dose in anthracycline-containing regimens on acute gastrointestinal symptoms associated with breast cancer treatment

Ejemplares similares